At the time of writing, Lexeo Therapeutics Inc [LXEO] stock is trading at $9.63, down -0.93%. An important factor to consider is whether the stock is rising or falling in short-term value. The LXEO shares have gain 5.94% over the last week, with a monthly amount drifted -4.46%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lexeo Therapeutics Inc [NASDAQ: LXEO] stock has seen the most recent analyst activity on November 20, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $19. Previously, Guggenheim started tracking the stock with Buy rating on October 15, 2025, and set its price target to $30. On July 31, 2025, Oppenheimer initiated with an Outperform rating and assigned a price target of $20 on the stock. Robert W. Baird started tracking the stock assigning an Outperform rating and suggested a price target of $28 on June 13, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $22 as its price target on June 06, 2024. Stifel started tracking with a Buy rating for this stock on November 28, 2023, and assigned it a price target of $20. In a note dated November 28, 2023, RBC Capital Mkts initiated an Outperform rating and provided a target price of $22 on this stock.
For the past year, the stock price of Lexeo Therapeutics Inc fluctuated between $1.45 and $10.38. Currently, Wall Street analysts expect the stock to reach $19.8 within the next 12 months. Lexeo Therapeutics Inc [NASDAQ: LXEO] shares were valued at $9.63 at the most recent close of the market. An investor can expect a potential return of 105.61% based on the average LXEO price forecast.
Analyzing the LXEO fundamentals
Gross Profit Margin for this corporation currently stands at -0.28% with Operating Profit Margin at -63.49%, Pretax Profit Margin comes in at -58.73%, and Net Profit Margin reading is -58.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -0.95 and Total Capital is -0.85. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.29 points at the first support level, and at 8.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.96, and for the 2nd resistance point, it is at 10.28.
Ratios To Look Out For
It is important to note that Lexeo Therapeutics Inc [NASDAQ:LXEO] has a current ratio of 7.40. On the other hand, the Quick Ratio is 7.40, and the Cash Ratio is 1.12.
Transactions by insiders
Recent insider trading involved Townsend Richard Nolan, Chief Executive Officer, that happened on Nov 18 ’25 when 1127.0 shares were sold. Chief Medical Officer, Adler Eric completed a deal on Nov 18 ’25 to sell 615.0 shares. Meanwhile, Chief Development Officer See Tai Sandi sold 386.0 shares on Nov 18 ’25.
